02:43 , Jun 1, 2019 |  BioCentury  |  Product Development

ASCO 2019 abstracts show solid tumor race heating up among bispecifics and CAR Ts

While strong progress in CAR T therapies will again feature at this year’s ASCO meeting, bispecific antibodies are having a moment -- making more inroads into solid tumors than CAR Ts and branching out via...
07:00 , Aug 4, 2016 |  BC Innovations  |  Targets & Mechanisms

Cereblon ambition

Most anti-cancer strategies aim to block overactive proteins by directly inhibiting their activity, but a growing number of companies are developing ways to tag the proteins for destruction by recruiting the enzymes that shuttle them...
07:00 , Jul 28, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Glutathione S-transferase π 1 (GSTP1); cereblon (CRBN)

Cancer INDICATION: Acute myelogenous leukemia (AML) Cell culture, in vitro and patient sample studies identified a promoter of CRBN-mediated GSTP1 degradation that could help treat AML. Screening of thalidomide analogs in human AML cell lines...
07:00 , Jun 9, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Glutathione S-transferase pi 1 (GSTP1)

Cancer INDICATION: Breast cancer Patient sample, cell culture and mouse studies suggest inhibiting GSTP1 could help treat triple-negative breast cancer (TNBC). Levels of GSTP1 were higher in TNBC cell lines and TNBC tumor samples from...
07:00 , Aug 4, 2014 |  BioCentury  |  Emerging Company Profile

Myelo: Preventing neutropenia

Myelo Therapeutics GmbH is developing a small molecule that could provide a cheaper and safer alternative to standard of care G-CSF to prevent and to treat chemotherapy-induced neutropenia. Neutropenia is a decrease in levels of...
07:00 , May 19, 2014 |  BC Week In Review  |  Company News

MabVax, Telik deal

The cancer companies will merge in a stock deal to create a publicly traded company named MabVax Therapeutics Holdings Inc. Telik shareholders will own 15% of the combined company, and MabVax shareholders will own the...
07:00 , Aug 29, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Nerve damage Low-density lipoprotein-related protein 1 a-2-macroglobulin receptor (LRP1; CD91); neurotrophic tyrosine kinase receptor 3 (NTRK3; TrkC) Cell culture and rat...
07:00 , Apr 15, 2013 |  BC Week In Review  |  Company News

Terrapin, Taiho deal

The companies entered into a definitive agreement to advance the development of Terrapin's TER286 broad spectrum cancer compound. Taiho will provide R&D funding and Terrapin will be responsible for preclinical testing and preparation for an...
07:00 , Apr 15, 2013 |  BC Week In Review  |  Company News

Oncor, The Johns Hopkins University deal

Oncor licensed a patent from the university for genetic diagnosis of prostate cancer. The company said the technology demonstrated that loss of expression of the glutathione-S-transferase gene (GSTP1) predicts development of prostate cancer. GSTP1 expression...
08:00 , Feb 4, 2013 |  BC Week In Review  |  Company News

Epigenomics, Predictive Biosciences sales and marketing update

The partners said Predictive Biosciences launched a biopsy test to diagnose prostate cancer in the U.S. that incorporates Epigenomics' glutathione S-transferase pi 1 ( GSTP1 ) DNA methylation marker. In 2010, Predictive exercised a 2009...